<p>Human papillomavirus associated head and neck cancer (HPV + HNC) is rising globally, emphasizing the need for improved therapeutic and screening strategies. To test novel therapies and study HPV-related disease progression, it is vital to develop relevant preclinical models. However, many fail to address critical concerns, including generating a representative immune microenvironment and adequately modeling HPV-driven malignant transformation. Recent multi-omics studies reveal the significance of HPV integration location in HPV-related carcinogenesis and highlight the necessity of targeted treatment methods. Thus, we have developed a murine model of HPV16 + HNC modifying the published CRISPR-based Somatic Oncogene kNock-In for Cancer Modeling (CRISPR-SONIC) system for precise integration of HPV oncogenes. We showed that CRISPR-SONIC knock-in of <i>Kras</i><sup><i>G12D</i></sup>, HPV16 E6 and E7, and a luciferase reporter at the murine β-actin 3’-UTR locus could induce spontaneous buccal tumors with sarcomatous morphology under transient or selective immunosuppression. Both preventative and therapeutic pNGVL4a-CRT/E7(detox) DNA vaccination could induce HPV16 E7-specific immune response and reduce tumor growth. Furthermore, CRISPR-SONIC knock-in of HPV16 E6 and E7 with co-delivery of HNC-relevant oncogenes <i>AKT</i> and <i>c-Myc</i> produced tumors in NSG mice capturing the characteristic carcinomic morphology of HPV + HNC. Overall, our model offers a robust platform for evaluating new therapies and exploring HPV-related carcinogenesis. </p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Generation of a spontaneous murine HPV + oral cancer model with site-specific oncogene insertion using CRISPR-SONIC

  • Julia Tao,
  • Jason Murray,
  • Hsin-Fang Tu,
  • Darrell Fan,
  • Ya-Chea Tsai,
  • Ming-Hung Hu,
  • Annie A. Wu,
  • Deyin Xing,
  • Chien-Fu Hung,
  • T.-C. Wu

摘要

Human papillomavirus associated head and neck cancer (HPV + HNC) is rising globally, emphasizing the need for improved therapeutic and screening strategies. To test novel therapies and study HPV-related disease progression, it is vital to develop relevant preclinical models. However, many fail to address critical concerns, including generating a representative immune microenvironment and adequately modeling HPV-driven malignant transformation. Recent multi-omics studies reveal the significance of HPV integration location in HPV-related carcinogenesis and highlight the necessity of targeted treatment methods. Thus, we have developed a murine model of HPV16 + HNC modifying the published CRISPR-based Somatic Oncogene kNock-In for Cancer Modeling (CRISPR-SONIC) system for precise integration of HPV oncogenes. We showed that CRISPR-SONIC knock-in of KrasG12D, HPV16 E6 and E7, and a luciferase reporter at the murine β-actin 3’-UTR locus could induce spontaneous buccal tumors with sarcomatous morphology under transient or selective immunosuppression. Both preventative and therapeutic pNGVL4a-CRT/E7(detox) DNA vaccination could induce HPV16 E7-specific immune response and reduce tumor growth. Furthermore, CRISPR-SONIC knock-in of HPV16 E6 and E7 with co-delivery of HNC-relevant oncogenes AKT and c-Myc produced tumors in NSG mice capturing the characteristic carcinomic morphology of HPV + HNC. Overall, our model offers a robust platform for evaluating new therapies and exploring HPV-related carcinogenesis.